Adults 18 to 30, any sex, with Hookah Smoking. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Perceived HarmPrimary· 6-months
Perceived harm of hookah tobacco is measured using valid self-report item assessing perceptions of how likely harms are to occur from hookah tobacco use (response range 1 no chance to 7 certain to happen). Greater perceived likelihood of harm is considered a better outcome. The assessment is administered immediately post intervention, 3-month follow-up, and 6-month follow-up, 6 month follow-up data reported.
Group
Value
95% CI
Control
4.1
3.9 – 4.4
Untailored Messages
4.2
4.0 – 4.5
Tailored Messages
4.5
4.2 – 4.8
Perceived AddictivenessPrimary· 6-months
Perceived addictiveness of hookah tobacco is measured using valid self-report item assessing perceptions of how likely one is to become addicted to hookah tobacco (1 = no chance, 7 = certain to happen). Greater perceived likelihood of addictiveness is considered a better outcome. The assessment is administered immediately post-intervention, 3-month follow-up, and 6 month follow-up, 6-month follow-up data reported.
Group
Value
95% CI
Control
3.9
3.5 – 4.2
Untailored Messages
3.9
3.6 – 4.3
Tailored Messages
4.0
3.7 – 4.3
Worry About HarmPrimary· 6-months
Worry about the harms of hookah tobacco is measured using a valid self-report item assessing how much participants worry about the risks of hookah tobacco (1 = Not at all, 7 = Very much). Greater worry about harm is considered a better outcome. The assessment is administered immediately post-intervention, 3-month follow-up, and 6 month follow-up, 6-month follow-up reported.
Group
Value
95% CI
Control
4.6
4.3 – 5.0
Untailored Messages
4.1
3.8 – 4.5
Tailored Messages
4.6
4.3 – 5.0
Worry About AddictivenessPrimary· 6 months
Worry about the addictiveness of hookah tobacco is measured using a valid self-report item assessing how much participants worry about becoming addicted to hookah tobacco (1 = Not at all, 7 = very much). Greater perceived addictiveness is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month-follow-up, 6 month follow-up reported.
Group
Value
95% CI
Control
3.6
3.2 – 3.9
Untailored Messages
3.7
3.3 – 4.1
Tailored Messages
3.9
3.5 – 4.3
Motivation to QuitPrimary· 6-months
Motivation to quit is measured using a valid self-report item assessing how much participants want to quit smoking hookah tobacco right now (1 = Not at all, 7 = Very). Greater motivation to quit is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up reported.
Group
Value
95% CI
Control
4.0
3.5 – 4.4
Untailored Messages
4.0
3.5 – 4.4
Tailored Messages
3.5
3.0 – 4.1
Hookah Tobacco Use FrequencyPrimary· 6 months
Hookah tobacco use frequency is measured using a valid self-report item assessing how often participants have smoked hookah tobacco in the past 30 days. The item measures the number of days in the past month participants have smoked hookah tobacco. Less frequent hookah tobacco use is considered a better outcome. The assessment is administered immediately post-intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up reported.
Group
Value
95% CI
Control
4.3
3.0 – 5.6
Untailored Messages
4.0
2.6 – 5.2
Tailored Messages
3.5
2.0 – 5.0
Percent of Participants Who Quit Smoking Hookah TobaccoPrimary· 6 months
Hookah tobacco cessation is measured using a single valid self-report item assessing if participants have stopped smoking hookah tobacco completely. The item asks if participants have completely stopped smoking hookah tobacco based on a yes/no response. Quitting hookah tobacco use (i.e., responses of "yes") is considered a better outcome. The assessment is administered immediately post intervention, 3 month follow-up, and 6 month follow-up, 6-month follow-up data reported.
Group
Value
95% CI
Control
29.20
Untailored Messages
37.96
Tailored Messages
48.98
Sponsor's own description
The objective of this study is to examine whether messages conveying the harms and addictiveness of waterpipe (i.e., hookah) tobacco delivered by mobile phone multimedia messaging (MMS) are effective for promoting hookah tobacco cessation among young adults ages 18 to 30 years.
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
NCT04661683 — Secondhand Effects of Hookah (i.e., Waterpipe) Smoke and Aerosol
· NA
· recruiting
Other Georgetown University trials
Trials by the same sponsor.
NCT07228000 — Bundled Cancer Screening and Genetic Services Navigation
· NA
· not yet recruiting
NCT07128927 — Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors
· NA
· recruiting
NCT06046287 — Daratumumab for Polyneuropathy Associated With MGUS
· Phase 2
· withdrawn
NCT06980103 — Use of a Decision Aid to Resolve Uncertainty About Radioactive Iodine Treatment in Patients With Intermediate Risk Thyro
· NA
· recruiting
NCT07105358 — Visual Plasticity Following Brain Lesions
· NA
· recruiting
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Georgetown University
Last refreshed: 20 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03595280.